OctoPlus N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
18 apr 2010 - 22:03
Statutaire naam
OctoPlus N.V.
Titel
OctoPlus' licensee Biolex makes third presentation at EASL confirming Locteron' superior product profile
Bericht
OctoPlus N.V. (“OctoPlus” or the “Company”) (Euronext: OCTO) announces that its licensee Biolex Therapeutics gave a presentation on Friday, during the 45th International Liver Congress (EASL) in Austria, to present interim clinical results from its Phase IIb clinical study with Locteron® named the “480 STUDY”.
The main conclusion from the two posters and the oral presentation that were given during the EASL conference is that Locteron dosed every other week consistently achieves a reduction in flu-like sides effects while maintaining antiviral efficacy comparable to the weekly dosed standard of care, providing compelling proof that Locteron offers a significant improvement in interferon therapy.
Datum laatste update: 01 september 2024